All Stories
Subscribe to AGENNIX AG i.L.

30.01.2012 – 10:53


Agennix AG to Present at Three Conferences in February

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and Houston,
TX, January 30, 2012 - Agennix AG (Frankfurt Stock Exchange: AGX) today
announced that the Company will be presenting at three conferences in February. 

Close Brothers Seydler Bank AG Small and Mid Cap Conference, Frankfurt
Agennix will give a presentation at the Close Brothers Seydler Bank AG Small and
Mid Cap Conference. The presentation will be on Wednesday, February 1, 2012, at
12:30 CET at the IHK Frankfurt (Boerse), Frankfurt am Main, Germany.

German Science Day, Berlin
The Company will give a presentation and participate in a panel discussion on
cancer immunotherapies and oligonucleotides as part of German Science Day at the
University hospital Charité in Berlin, Germany. The presentation is scheduled
for Thursday, February 2, 2012, at 15:35 CET. A live webcast of the presentation
in German will be available through the Agennix Web site at A
replay in German and English will be available on the Web site following the
live event.

The First German Science Day - Fight Cancer, an initiative of the German
biotechnology industry, will take place on the occasion of World Cancer Day. The
event will highlight the major research and development contributions of German
biotechnology companies working in the field of cancer to the press, investors
and analysts. More information on German Science Day (German language only) can
be found at

BIO CEO & Investor Conference, New York City 
Agennix will also give a presentation at the 14th Annual BIO CEO & Investor
Conference in New York, NY, USA. The presentation is scheduled for Tuesday,
February 14, 2012 at 11:00 AM ET/17:00 CET at the Waldorf Astoria Hotel. A live
audio webcast will be available through the Agennix Web site at
A replay will be available on the Web site following the live event.

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially improve
the length and quality of life of critically ill patients in areas of major
unmet medical need. The Company's most advanced program is talactoferrin, an
oral immunotherapy that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer and in severe
sepsis. Talactoferrin is currently in Phase III clinical trials in non-small
cell lung cancer and in a Phase II/III trial in severe sepsis. Other clinical
development programs include RGB-286638, a multi-targeted kinase inhibitor in
Phase I testing for cancer, and a topical gel form of talactoferrin for diabetic
foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company
has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and
Houston, Texas. For additional information, please visit the Agennix Web site at

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. The achievement of
positive results in early stage clinical studies does not ensure that later
stage or large scale clinical studies will be successful.  Even if the results
from our later stage trials with talactoferrin, including the ongoing FORTIS-M
trial in non-small cell lung cancer, are considered positive, there can be no
guarantee that they will be sufficient to gain marketing approval in the United
States or any other country, and regulatory authorities may require additional
information, data and/or further pre-clinical or clinical studies to support
approval.  In such event, there can be no guarantee that the Company will have
or be able to obtain the financial resources to conduct any such additional
studies or that such studies will yield results sufficient for approval. 
Forward-looking statements speak only as of the date on which they are made and
Agennix undertakes no obligation to update these forward-looking statements,
even if new information becomes available in the future.

Agennix(TM) is a trademark of the Agennix group.

Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications 		
Phone: +49 (0)89 8565 2693
In den USA: Laurie Doyle		
Senior Director, Investor Relations & Corporate Communications		
Phone: +1 609 524 5884
Additional media contact for Europe:
MC Services AG	
Raimund Gabriel	
Phone: +49 (0) 89 210 228 0
Additional investor contact for Europe:
Trout International LLC	
Lauren Williams, Senior Vice President	
Phone: +44 207 936 9325

end of announcement                               euro adhoc 

company:     AGENNIX AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 89 8565 2693
FAX:         +49 89 8565 2610
sector:      Pharmaceuticals
ISIN:        DE000A1A6XX4
indexes:     CDAX, Prime All Share, Technology All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
             regulated dealing/prime standard: Frankfurt 
language:   English

Original content of: AGENNIX AG i.L., transmitted by news aktuell

More stories: AGENNIX AG i.L.
More stories: AGENNIX AG i.L.